A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users
Study Details
Study Description
Brief Summary
This randomized, placebo- and active-controlled, crossover study will evaluate the abuse liability potential of RO4917838 in recreational drug users. In a pre-study (Part 1), subjects will receive a single dose of either diazepam or placebo in an inpatient crossover design, with a wash-out period of at least 10 days between treatments. Subjects who are clearly able to distinguish the positive control from placebo will be enrolled in the main study (Part 2) and will be randomized to single oral doses of RO4917838 (3 dose levels), diazepam and placebo in a double-blind, double-dummy inpatient crossover design. Washout-periods between the 5 treatment periods in Part 2 will be at least 10 days.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: A
|
Drug: diazepam
Single dose
|
| Placebo Comparator: B
|
Drug: Placebo
Single dose
|
| Experimental: C
|
Drug: RO4917838
Single doses (3 dose levels)
|
Outcome Measures
Primary Outcome Measures
- Pharmacodynamics: Abuse potential measured by Visual analogue scales (VAS) [approximately 11 months]
Secondary Outcome Measures
- Safety: Incidence of adverse events [approximately 11 months]
- Pharmacokinetics: plasma concentrations of RO4917838 [approximately 11 months]
- Pharmacodynamics: Addiction Research Center Inventory (ARCI) subscales [approximately 11 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy male or female volunteers, 18 to 55 years of age inclusive
-
Recreational drug abuse experience (>/= 10 times lifetime abuse of a CNS depressant,
/= 1 abuse of CNS depressant in the previous 3 months
-
Body mass index (BMI) 18 to 30 kg/m2 inclusive
-
Main study (Part 2): Able to differentiate between diazepam and placebo
Exclusion Criteria:
-
History of any significant disease or disorder
-
History or current diagnosis of substance dependence (excluding caffeine and nicotine)
-
Currently seeking or history of participating in treatment for substance-related disorders, including successful completion of such treatment
-
Any confirmed significant allergic reactions against any drug, or multiple allergies in the judgement of the investigator
-
Positive for hepatitis B, hepatitis C or HIV infection
-
Pregnant or lactating women
-
Participation in an investigational drug or device study within the last 30 days prior to Day 1 of the study
-
Confirmed positive drug screening at screening / any Day -1 (allowed positive THC at screening and any Day -1 and positive benzodiazepine at screening only)
-
Positive alcohol breath test at screening / any Day -1
-
Heavy smoker (> 20 cigarettes, > 8 pipefuls or > 8 cigars per day)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Salt Lake City | Utah | United States | 84106 |
Sponsors and Collaborators
- Hoffmann-La Roche
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BP25259